后大流行时期的生活238——“特效药”·其四【乐睿灵（来瑞特韦）】
什么是“来瑞特韦”
乐睿灵的药物原理
乐睿灵的药物效果
乐睿灵的药物安全
乐睿灵的药物特点
（每个治疗组不同时间点新冠病毒载量的变化）
（不同治疗组不同时间核酸转阴患者比例[安慰剂组、乐睿灵组、组合组]）
乐睿灵组的核酸转阴情况也要明显好于安慰剂组。
乐睿灵组与安慰剂组相比，在症状恢复方面大约可以提前将近一天的时间；
病毒载量数据显示，受试人群在治疗后第4天病毒载量较基线变化与安慰剂组相比明显下降且具有统计学差异；
乐睿灵的总体研究显示其安全耐受性良好；
乐睿灵不需与利托那韦，适用人群更加广泛，药物冲突更少；
[1]国家药品监督管理局，国家药监局附条件批准新冠病毒感染治疗药物来瑞特韦片上市，2023-03-23
https://www.nmpa.gov.cn/yaowen/ypjgyw/ypyw/20230323145807117.html
[2]Yan W, Zheng Y, Zeng X, He B, Cheng W. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduct Target Ther. 2022 Jan 27;7(1):26. doi: 10.1038/s41392-022-00884-5. PMID: 35087058; PMCID: PMC8793099.
[3]Wang B, Li HJ, Cai MM, Lin ZX, Ou XF, Wu SH, Cai RH, Wei YN, Yang F, Zhu YM, Yang ZF, Zhong NS, Lin L. Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial. EClinicalMedicine. 2023 Aug 31;63:102189. doi: 10.1016/j.eclinm.2023.102189. PMID: 37692076; PMCID: PMC10484968.
[4]Zhan Y, Lin Z, Liang J, Sun R, Li Y, Lin B, Ge F, Lin L, Lu H, Su L, Xiang T, Pan H, Huang C, Deng Y, Wang F, Xu R, Chen D, Zhang P, Tong J, Wang X, Meng Q, Zheng Z, Ou S, Guo X, Yao H, Yu T, Li W, Zhang Y, Jiang M, Fang Z, Song Y, Chen R, Luo J, Kang C, Liang S, Li H; other Collaborative Institutes; Zheng J, Zhong N, Yang Z. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. EClinicalMedicine. 2023 Dec 14;67:102359. doi: 10.1016/j.eclinm.2023.102359. PMID: 38188690; PMCID: PMC10770433.
[5]Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, Ichihashi G, Sanaki T, Baba K, Tsuge Y, Uehara T. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. Clin Infect Dis. 2023 Apr 17;76(8):1403-1411. doi: 10.1093/cid/ciac933. PMID: 36477182; PMCID: PMC10110269.
[6]乐睿灵（来瑞特韦片）药品说明书.
[7]Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clin Pharmacol Ther. 2022 Dec;112(6):1191-1200. doi: 10.1002/cpt.2646. Epub 2022 Jun 7. PMID: 35567754; PMCID: PMC9348462.
[8]Zhang H, Zhou J, Chen H, Mao J, Tang Y, Yan W, Zhang T, Li C, Chen S, Li G, Zhang G, Ding Y, Liu L. Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171. Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0111523. doi: 10.1128/aac.01115-23. Epub 2023 Dec 15. PMID: 38099673; PMCID: PMC10777829.
[9]Wang F, Xiao W, Tang Y, Cao M, Shu D, Asakawa T, Xu Y, Jiang X, Zhang L, Wang W, Tang J, Huang Y, Yang Y, Yang Y, Tang R, Shen J, Lu H. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial. Lancet Reg Health West Pac. 2023 Jul 11;38:100835. doi: 10.1016/j.lanwpc.2023.100835. PMID: 37484496; PMCID: PMC10362366.
[10]福建广生堂药业股份有限公司，关于一类创新药泰中定（阿泰特韦片联合利托那韦片）获得国家药品监督管理局批准上市的公告.
https://pdf.dfcfw.com/pdf/H2_AN202311241612250764_1.pdf?1700858985000.pdf
[11]国家医保局 人力资源社会保障部关于印发《国家基本医疗保险、工伤保险和生育保险药品目录（2023年）》的通知
http://www.nhsa.gov.cn/art/2023/12/13/art_104_11673.html